Lilly predicts it will achieve an adjusted profit of between $23.00 and $23.70 per share this year, an increase on its ...

Get the latest on Novo Nordisk's Alzheimer's trial, stock outlook, and market risks. See what investors need to know before ...

October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound ...

The US pharmaceutical company Eli Lilly has met with the Department of Enterprise to express concerns about planned changes to the patent law in Europe. The multinational, which employs 3,500 people ...

Novo Nordisk's Alzheimer's trial really is like a lottery ticket. If it wins, the company gains a transformational new market ...

The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 ...

The availability of a rule-in-rule-out test for Alzheimer’s disease in primary care settings is likely to drive efficiencies throughout the care continuum.

Basketball legend, entrepreneur and entertainer Shaquille O'Neal partners with Lilly to shine a spotlight on moderate-to-severe obstructive sleep apnea (OSA), encouraging ...

The US FDA has granted clearance for Roche's Elecsys pTau181 test for the preliminary evaluation of Alzheimer's disease.

Until recently, GLP -1s, a powerful new class of weight-loss drugs, were confined mostly to rich countries. Yet the World ...

A second blood test has been been approved by the US Food and Drug Administration to assist in diagnosing Alzheimer’s disease ...

The WHO calls for increased policy focus on neurological disorders like Alzheimer’s disease, an indication that has seen ...